Conference Coverage
Conference Coverage
Is additional treatment needed, pretransplant, for r/r AML?
The issue of whether or not patients with r/r AML require additional treatment pretransplant was debated at SOHO 2023.
Conference Coverage
Using JAK inhibitors for myelofibrosis
Newer options are improving management of cytopenic patients.
Conference Coverage
CHP/CCUS: Low blood cancer risk for most patients
The goal of ongoing research is to prevent CHIP/CCUS progression in higher-risk patients.
Conference Coverage
Genetic profiles affect smokers’ lung cancer risk
“This is the first study to validate genetic factors associated with people who appear to be resistant to developing tobacco-related lung cancer...
Conference Coverage
Do some randomized controlled trials stack the deck?
“In the ethical design of clinical trials, patients make important sacrifices to participate, and in exchange, the academic and clinical...
Conference Coverage
‘Treatment holiday’ in prostate cancer with tailored dosing
“Personalizing dosing intervals using early-response biomarkers with 177Lu-PSMA has the potential to achieve similar overall treatment...
Conference Coverage
Quizartinib boosts AML survival, regardless of SCT
The FLT-inhibitor drug shows survival benefits in patients with higher-risk FLT3 mutations, with or without prior stem cell transplant.
Conference Coverage
SCD, beta-thalassemia: CRISPR-based gene therapy `transformative’
Phase 3 results suggest potential for a “functional cure”; this treatment could become first-ever approved CRISPR gene-editing therapy.
Latest News
Residency match process under scrutiny again, this time by AMA
AMA may study alternatives to the current residency matching program in an effort to improve residents’ compensation and other job-related issues...
Latest News
Imaging techniques will revolutionize cancer detection, expert predicts
Jennifer Barton, PhD, and her colleagues are developing an OCT/fluorescence imaging falloposcope that is 0.8 mm in diameter, flexible, and...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...